Evotec SE — Regulatory Filings 2002

Nov 25, 2002

News Details

Corporate | 25 November 2002 08:42

Evotec OAI AG english

Evotec OAI Extends Discovery Agreement with Solvay Pharmaceuticals Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– Hamburg, Germany | Abingdon, UK – Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today a one-year extension of its Focused Library Agreement with Solvay Pharmaceuticals which was originally signed in January 2001. Applying Evotec OAI’s world class expertise in high-speed and computational chemistry, a dedicated team of Evotec OAI chemists will design and synthesise collections of small, drug-like molecules around selected Solvay templates. Solvay will use these high-quality compounds in screens against their targets to identify novel drug candidates. Evotec OAI has the potential to earn further clinical and market milestones. Joern Aldag, President and Chief Executive Officer of Evotec OAI, commented: “This collaboration has set a standard on how we work collaboratively with our partners. Over the past two years we have demonstrated that our drug discovery expertise adds significant value to Solvay’s programmes. We are delighted that Solvay decided to continue the partnership with Evotec OAI and to become one of our multi-year discovery partners.” Dr Jan van Randen, Technology Development Head of Solvay Pharmaceuticals, added: “Our partnership with Evotec OAI has proven to be extremely successful as it resulted in the timely delivery of excellent sci- entific results. We are particularly impressed by Evotec OAI’s wealth of chemistry talent which led to novel, innovative approaches in creating drug-like molecules around Solvay’s templates.” end of message, (c)DGAP 25.11.2002 ——————————————————————————– WKN: 566480; ISIN: DE0005664809; Index: NEMAX-50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 250842 Nov 02